Production (Stage)
Evofem Biosciences, Inc.
EVFM
$0.01
$0.00044.17%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.61M | 19.36M | 17.10M | 17.71M | 16.01M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.61M | 19.36M | 17.10M | 17.71M | 16.01M |
| Cost of Revenue | 3.52M | 3.83M | 3.28M | 4.30M | 5.82M |
| Gross Profit | 13.09M | 15.53M | 13.82M | 13.42M | 10.19M |
| SG&A Expenses | 26.17M | 26.37M | 21.00M | 21.73M | 24.37M |
| Depreciation & Amortization | 842.00K | 619.00K | 301.00K | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.11M | 27.04M | 27.15M | 28.88M | 33.12M |
| Operating Income | -4.51M | -7.68M | -10.05M | -11.17M | -17.11M |
| Income Before Tax | -3.10M | -8.86M | -7.94M | 60.45M | 50.54M |
| Income Tax Expenses | 0.00 | 0.00 | 0.00 | 19.00K | 14.00K |
| Earnings from Continuing Operations | -3.10 | -8.86 | -7.94 | 60.43 | 50.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.10M | -8.86M | -7.94M | 60.43M | 50.52M |
| EBIT | -4.51M | -7.68M | -10.05M | -11.17M | -17.11M |
| EBITDA | -3.64M | -7.03M | -9.71M | -11.09M | -16.87M |
| EPS Basic | -0.03 | -0.19 | -0.60 | 15.01 | 9.56 |
| Normalized Basic EPS | -0.01 | -0.14 | -0.23 | -1.59 | -5.00 |
| EPS Diluted | -0.06 | -0.22 | -0.91 | -0.79 | -6.22 |
| Normalized Diluted EPS | -0.03 | -0.15 | -0.25 | -0.24 | -3.63 |
| Average Basic Shares Outstanding | 382.37M | 300.21M | 206.09M | 113.86M | 48.67M |
| Average Diluted Shares Outstanding | 7.86B | 1.85B | 1.75B | 2.39B | 774.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |